Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
As Published on the DePuy Hip Replacement Recall Website
With complaints about the DePuy hip replacementrecall continuing to escalate, Johnson & Johnson(J&J) has added another rec...
The announcement of its new recall of Eprexsyringes because some batches may not be aspotent as they should be further com...
DePuy       Orthopedics     Inc.’s                         announcement of a worldwide                         recall of t...
J&J has been questioned after it hired BroadSpireServices to handle the hip replacement recall. Byputting victims under th...
With the most recent one in August this yearinvolving almost 2.5 million packages of a TylenolCold product, the Eprex inci...
J&J is continuing to overhaul its quality controland manufacturing processes, and its slowlygetting some long-absent consu...
Upcoming SlideShare
Loading in …5
×

J&J Adds Eprex To Recall Tally On Top Of DePuy Hip Replacement

877 views

Published on

http://www.depuyhipreplacementlawsuit.com/ With complaints about the DePuy hip replacement recall continuing to escalate, Johnson & Johnson (J&J) has added another recall, this time on 200,000 syringes of its Eprex anemia drug. A New York Times analysis has estimated that the hip replacement recall would cost J&J about $1 billion. With some artificial joint manufacturers talking of offshoring in wake of medical device excise tax, J&J would be hard pressed to prove its claim that the DePuy recall is not expected to have a material adverse effect on the company’s financial position.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

J&J Adds Eprex To Recall Tally On Top Of DePuy Hip Replacement

  1. 1. As Published on the DePuy Hip Replacement Recall Website
  2. 2. With complaints about the DePuy hip replacementrecall continuing to escalate, Johnson & Johnson(J&J) has added another recall, this time on 200,000syringes of its Eprex anemia drug. A New YorkTimes analysis has estimated that the hipreplacement recall would cost J&J about $1 billion.With some artificial joint manufacturers talking ofoffshoring in wake of medical device excise tax, J&Jwould be hard pressed to prove its claim that theDePuy recall is not expected to have a materialadverse effect on the company’s financial position.
  3. 3. The announcement of its new recall of Eprexsyringes because some batches may not be aspotent as they should be further complicatesJ&J’s new statement. The company believesthat only 6,300 Eprex syringes remain on themarket with the rest already used in some 17countries where the batches were distributed.J&J said that no adverse events have beenreported despite this.
  4. 4. DePuy Orthopedics Inc.’s announcement of a worldwide recall of two of its hip replacement systems, the ASR XL Acetabular System and the DePuy ASR Hip Resurfacing Platform August of 2010 was its most high profile recall to date.With the British Joint Registry estimating that nearly onethird of the hip implant will fail after six years andDePuy already accounting for 75 percent of the 5,000complaints on hip replacement received by the U.S.Food and Drug Administration (FDA) this year so far,more complaints are expected to be filed. For the lasttwo months alone, about 700 lawsuits have also beenfiled against J&J.
  5. 5. J&J has been questioned after it hired BroadSpireServices to handle the hip replacement recall. Byputting victims under the care of doctors on J&J’spayroll, not the patient’s own doctor, and requiringthose patients to hand over medical records thecompany would not normally get a look at unlessthe patient was represented by an attorney, J&Jhave been accused of trying to cut on thesettlement expenses and taking advantage ofpatients.
  6. 6. With the most recent one in August this yearinvolving almost 2.5 million packages of a TylenolCold product, the Eprex incident follows a slew ofconsumer-drug recalls. Bottles of its epilepsydrug Topamax, its atypical antipsychotic Risperdaland its HIV treatment Prezista were some otherprescription drugs pulled out by the company--aswell as leaky insulin cartridges and potentiallyunsterile drug sutures.
  7. 7. J&J is continuing to overhaul its quality controland manufacturing processes, and its slowlygetting some long-absent consumer drugs backto market. However, its CEO William Weldonadmitted that the company has some ground tomake up with consumers to mend its now-tattered reputation for high-quality products.Damage has already been done with 93,000people worldwide having received the DePuy hipimplants despite J&J’s DePuy hip replacementrecall.

×